House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Urology

Urological infections

EAU · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

Selected EAU 2026 recommendations covering urinary infection classification, asymptomatic bacteriuria, cystitis and recurrence, pyelonephritis, catheter-associated infection and procedural prevention. Treatment decisions depend on the infection site, severity, susceptibility results and local resistance patterns.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Classify infection and avoid unnecessary treatment

  • Distinguish localised cystitis without systemic features from systemic UTI, which may occur with or without local urinary symptoms. Assess urinary abnormalities, catheters, previous antibiotics, renal impairment and other factors that could impair treatment response. [1]
  • Do not screen for or treat asymptomatic bacteriuria in women without risk factors, well-controlled diabetes, postmenopausal women, institutionalised older people, reconstructed or dysfunctional lower urinary tracts, renal transplant recipients, before arthroplasty, or recurrent UTI. [1]
  • Screen for and treat asymptomatic bacteriuria before urological procedures that breach mucosa. Pregnancy screening and short-course treatment or single-dose fosfomycin carry a weak recommendation; consult national pregnancy guidance because the supporting evidence is low quality. [1]

Diagnose and treat cystitis

  • In women without other risk factors for systemic infection, diagnose cystitis from dysuria, frequency or urgency and absence of vaginal discharge. Obtain culture for suspected systemic infection, atypical symptoms, resistance risk, pregnancy, or symptoms persisting or recurring within four weeks after treatment. [1]
  • Discuss antibiotic-sparing approaches with women and explain the evidence. Non-antibiotic treatment is an option in non-geriatric patients through shared decisions that acknowledge greater symptom burden and a slightly increased risk of complications such as pyelonephritis. [1]
  • For cystitis in women, first-line options are fosfomycin trometamol, pivmecillinam, nitrofurantoin or nitroxoline. Choose according to susceptibility, efficacy, tolerability, ecological effects and availability. Do not routinely substitute aminopenicillins or fluoroquinolones; European fluoroquinolone restrictions allow use only when usual alternatives are inappropriate. [1]
  • For nitrofurantoin in younger men with localised cystitis, reliably exclude prostatic involvement first; the guideline does not establish an optimal treatment duration in men. [1]

Prevent recurrent cystitis

  • Confirm recurrent cystitis by urine culture. Avoid extensive routine investigation in women younger than 40 with no risk factors, but investigate atypical cases promptly when stones, obstruction, interstitial cystitis or urothelial cancer are suspected. [1]
  • Use vaginal oestrogen to prevent recurrence in postmenopausal women and methenamine hippurate in women without urinary tract abnormalities. Increasing fluid intake in premenopausal women is a weaker preventive recommendation. [1]
  • Reserve continuous or postcoital antimicrobial prophylaxis for recurrence after non-antimicrobial approaches have failed, discussing adverse effects. Consider patient-initiated short treatment courses for people with good adherence. [1]

Pyelonephritis and systemic infection

  • For pyelonephritis, obtain urinalysis, urine culture and susceptibility testing, and image the urinary tract to exclude urgent urological disorders. Persistent fever after 48–72 hours or suspected complications warrants additional imaging. [1]
  • Patients admitted with pyelonephritis should start intravenous antibiotics. Change to oral treatment once clinically improving and able to tolerate oral fluids. Nitrofurantoin, oral fosfomycin and pivmecillinam must not be used for pyelonephritis. [1]
  • For hospitalised systemic UTI, choose initial intravenous treatment using local resistance data and previous cultures, then tailor to susceptibility. Empirical ESBL coverage is needed when community prevalence, prior cultures or antimicrobial exposure make ESBL infection more likely. [1]
  • Do not use empirical ciprofloxacin or other fluoroquinolones for systemic UTI in urology-department patients or after fluoroquinolone use within the previous six months. Identify and manage obstruction or other complicating urinary abnormalities alongside antibiotics. [1]
  • Review outpatients with pyelonephritis within 48–72 hours. Worsening, persistent symptoms despite appropriate treatment, or recurrence should prompt further assessment, repeat culture and susceptibility testing, and imaging when needed to identify delayed-recovery causes. [1]

Catheter-associated infection

  • Do not routinely culture asymptomatic catheterised patients or diagnose catheter-associated UTI from pyuria, cloudy urine or odour alone. These findings do not reliably distinguish infection from asymptomatic bacteriuria. [1]
  • Treat symptomatic catheter-associated infection according to localised or systemic UTI guidance, and replace or remove the catheter before antibiotics. Do not generally treat catheter-associated asymptomatic bacteriuria, except before traumatic urinary interventions such as transurethral prostate resection. [1]
  • Minimise catheter duration. Do not apply topical antiseptics or antimicrobials to the catheter, urethra or meatus, and do not use prophylactic antimicrobials to prevent catheter-associated UTI. Routine prophylaxis after removal or for intermittent self-catheterisation is also discouraged. [1]

Other urgent infections and procedure prevention

  • Never perform prostatic massage in acute bacterial prostatitis. Obtain urine culture and consider blood culture and blood count; treat acute bacterial prostatitis using the systemic UTI recommendations. [1]
  • In Fournier gangrene, start broad-spectrum antibiotics on presentation, refine according to cultures and response, and commence repeated surgical debridement within 24 hours. Adjunctive treatments are reserved for clinical trials. [1]
  • Do not give routine prophylaxis for cystoscopy or urodynamics. For shockwave lithotripsy with sterile urine, avoid prophylaxis; suspected infected stones or bacteriuria are exceptions. Use single-dose prophylaxis for percutaneous nephrolithotomy and prophylaxis for transurethral prostate resection. [1]
  • Prefer transperineal prostate biopsy to reduce infection and improve antibiotic stewardship. Omitting prophylaxis in patients without infection risk factors is a weak recommendation. For transrectal biopsy, use povidone-iodine rectal cleansing and culture-targeted or augmented prophylaxis; avoid fluoroquinolones under the European restriction. [1]

Limitations and use

  • This selected summary does not reproduce complete antimicrobial doses, durations or renal/pregnancy adjustments, nor the full urethritis, epididymitis, fungal, tuberculosis or viral infection pathways.
  • European recommendations and regulatory restrictions require adaptation to Indian availability, resistance patterns and national guidance.
  • The 2026 urosepsis chapter is under review and directs readers to separate sepsis guidance; this is not a resuscitation protocol.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Urological infections

    Selected recommendation material consulted

Clinical guideline

Publication details

Issuing organisation
EAU
Resource type
Clinical guideline · House clinical summary
Source setting
Europe

Earlier House summaries: urinary tract infection eau

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Classify infection and avoid unnecessary treatment
  • Diagnose and treat cystitis
  • Prevent recurrent cystitis
  • Pyelonephritis and systemic infection
  • Catheter-associated infection
  • Other urgent infections and procedure prevention
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House